Tvardi Therapeutics, Inc. (TVRD)
TVRD Stock Price Chart
Explore Tvardi Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze TVRD price movements and trends.
TVRD Company Profile
Discover essential business fundamentals and corporate details for Tvardi Therapeutics, Inc. (TVRD) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
16 Apr 2025
Employees
17.00
CEO
Imran Alibhai
Description
Tvardi Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need. Their lead candidate, TTI-101, is currently in Phase 2 clinical trials for idiopathic pulmonary fibrosis (IPF) and hepatocellular carcinoma (HCC).
TVRD Financial Timeline
Browse a chronological timeline of Tvardi Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 May 2026
Upcoming earnings on 9 Mar 2026
Upcoming earnings on 12 Nov 2025
Earnings released on 14 Aug 2025
EPS came in at -$1.00 falling short of the estimated -$0.51 by -96.08%.
Earnings released on 13 May 2025
EPS came in at -$3.22 falling short of the estimated -$0.59 by -450.43%, while revenue for the quarter reached $2.57M .
TVRD Stock Performance
Access detailed TVRD performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.